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Available online 24 November 2016Increasing evidence has accrued which indicates that mesenchymal stem cells (MSCs) have a potential clinical
value in the treatment of certain diseases. Globally, nonalcoholic steatohepatitis (NASH) is awidespreaddisorder.
In the present study, MSCs were isolated successfully from compact bone and a mouse model of NASH was
established as achieved with use of a methionine-choline deﬁcient (MCD) diet. Compact bone-derived MSCs
transplantation reduced MCD diet-induced weight loss, hepatic lipid peroxidation, steatosis, ballooning, lobular
inﬂammation and ﬁbrogenesis. It was shown that MSCs treatment hampered MCD diet-induced proliferation of
CD4+ IFN-γ+ and CD4+IL-6+ T spleen cells. In addition, CD4+IL-17+ lymphocytes that associated with anti-in-
ﬂammation show little change inMCD aswell as inMCD+MSCs splenocytes.We conclude that MSCsmay have
a potential clinical value upon NASH, through their capacity to suppress activation of CD4+ IFN-γ+ and CD4+IL-
6+ lymphocytes.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Nonalcoholic steatohepatitis (NASH), progressive form of non-alco-
holic fatty liver disease (NAFLD), is a signiﬁcant predisposing factor for
the development of cryptogenic cirrhosis and hepatic failure [1,2]. The
prevalence of NAFLD correlates with the rising incidence of obesity
andmetabolic syndromes in thewesternworld [2]. In the United States,
the National Health and Nutrition Examination Surveys from 2009 to
2010 reported obesity rates of 35.5% among men and 35.8% among
women [3]. In Asia, prevalence of NAFLD has been found to be in the
range of 15–30% in the general population and exceeds 50% in patients
with diabetes andmetabolic syndromes [4]. In the general population of
the United States, the prevalence of NASH is approximately 3% but in-
creases to N25% in obese individuals [5]. Since the mid-1990s, ultra-
sound surveys for assessing fatty liver (any cause) were ﬁrst
published in mainland China [6,7]. From these surveys, the medianan Anatomy, Shanxi Medical
126.com (C. Liu).
B.V. This is an open access article uprevalence of ultrasonographic steatosis in the Chinese populations
was found to be 10%, but ranged from 1% to N30% [6,8].
Mesenchymal stem cells (MSCs) are a heterogeneous subset of stro-
mal stem cells that can be isolated from many adult tissues [9]. Within
the past few years,many studies have focused on the therapeutic effects
of different types of stem cells, which can improve liver function via dis-
tinct mechanisms [10]. Bone marrow-derived MSCs transplantation
was shown to be effective in rescuing experimental liver failure induced
by carbon tetrachloride gavage [11]. It was also reported that MSCs can
indirectly protect against hepatocyte death and increase survival in ful-
minant hepatic failure. Such effects resulted from the secretion of large
fractions of chemotactic, cytokines or chemokines by MSCs [12]. Others
have reported the hepatic engraftment of transplanted MSCs as ob-
served in sublethal animal models of liver injury, further signifying the
clinical potential for MSCs in the treatment of liver diseases [13–15].
However, the exact effects of MSCs upon NAFLD remain poorly
understood.
For a long time we have been interested in liver diseases. We have
demonstrated that adiponectin-derived active peptide ADP355
protected the mice from hepatic inﬂammation and ﬁbrosis [16]. We
have also been interested in the isolation and characterization of mes-
enchymal stem cells (MSCs) and in the potential application of these
cells to liver diseases especially [17,18]. We have used compact bone-nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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and their secreted molecules exhibited therapeutic potency in the
models of carbon tetrachloride-induced liver ﬁbrosis and
thioacetamide-induced fulminant hepatic failure (FHF) by function as
immuno-suppressor [19].
In the present study,we examined the effects ofMSCswithin NAFLD.
To accomplish this goal, a mouse model of NASH was induced by treat-
ment with a methionine-choline deﬁcient (MCD) diet, whose histolog-
ical changes occur rapidly and are morphologically similar to those
observed in human NASH [1]. MSCs were isolated from compact bone
according to procedures described previously [20]. We found that
NASH induced by a MCD diet was attenuated when treated with
MSCs, as indicated by reductions in weight loss, hepatic steatosis, hepa-
tocyte ballooning, liver inﬂammation and ﬁbrosis. The probable mecha-
nism of this MSC-mediated immunomodulation likely results from an
inhibition in the activation of CD4+ IFN-γ+ and CD4+IL-6+
lymphocytes.
2. Materials and methods
2.1. Animals and diet (Fig. 1)
Six- to eight-week-old male C57BL/6 mice were purchased from the
Academy of Military Medical Science (Beijing, China) and were main-
tained on a lipogenic diet deﬁcient in methionine and choline (MCD)
as obtained from TROPHIC Animal Feed High-tech Co., Ltd. (Nantong,
Jiangsu, China). The diet has made into solid by manufacturer and ad-
ministrated randomly. At ﬁrst, the mice were randomly divided into 2
groups: (i) Normal - controls fed with a regular diet, n = 6; (ii) MCD -
mice fed with the MCD diet, n = 12. Six weeks later, MCD - mice were
randomized into 2 groups again: (ii) MCD - mice as before, n = 6; (iii)
MCD+MSC -mice fedwith the MCD diet supplemented with an intra-
venously injection of 1 × 106MSCs administered at 6 and 7weeks of the
10-week experiment, n= 6. At 10weeks, all micewere euthanized and
tissue was harvested.
This experiment was approved by the Animal Ethics Committee of
Tianjin Medical University.
2.2. Isolation and culture of bone-derived MSCs
The way to isolate and culture mMSCs from murine compact bone
was modiﬁed from the previously described one [19]. In brief, we ﬁrst
pulled down the skin and cut many of the muscles that attached to
the hindlimbs and humeri by surgical scissors, and then disconnected
them from the trunk and at axillaries. Use two forceps to remove rem-
nants of the muscles and tendons attached to the bone. After boneFig. 1. Diagram of the experimental protocol. Themicewere randomly divided into 3 groups: (i
(iii) MCD+MSC -mice fedwith theMCD diet supplementedwith an intravenously injection o
mice were euthanized and tissue was harvested.marrow beingﬂushed and discardedwith PBS by a syringe, the compact
boneswere excised into chips of about 1mm,washedwith PBS until the
released cells were removed. Two weeks of being incubated in α-MEM
containing 10% FBS later, mMSCs sprouted from chips and permeated in
the dishes. Harvest the cells by a cell scraper. The primary obtained cells
were then passaged by 0.25% trypsin-EDTA (GIBCO) digestion. After 5–8
passages, cells were used for the following experiments.
2.3. Examination of immunophenotypic features of MSCs
MSCs prepared as described above were stained with the following
ﬂuorescein-linked antibodies: CD29, CD44, CD11b, CD45 or CD135 (all
from eBioscience, CA, USA). Cells were analyzed using a FACScalibur
(BD Biosciences, USA). Flow cytometry data were analyzed using Flow
Jo 7.6 software (BD Biosciences, USA).
2.4. Histology of livers
Livers were perfused with PBS, removed, weighed and sliced into
small sections (0.5 × 0.5 cm). Liver sections were embedded in parafﬁn
after being ﬁxed in 4% (weight/volume) paraformaldehyde and were
cut into 6-μm-thick sections. Parafﬁn sections were stained with hema-
toxylin–eosin (HE) for assessing inﬂammation and steatosis and
Picrosirius red for assessing ﬁbrosis.
Evaluation of the extent of resultant NASH [2] was performed using
the following scaling scores:
Steatosis. Hepatocytes containing fat vacuoles were subjectively vi-
sualized and graded according to the following scale: 0 - normal,
none of hepatocytes were affected, 1 - tiny, b5% of hepatocytes
were affected, 2 - mild, 5%–33% of hepatocytes were affected, 3 -
moderate, 34% - 66% of hepatocytes were affected and 4 - severe,
N66% of hepatocytes were affected.
Ballooning. 0 - none, 1 - rare or few, 2 - moderate and 3 - many.
Lobular inﬂammation. 0 - None, 1 - 1-2 foci/20 × ﬁeld, 2 - 2-4 foci/
20 × ﬁeld and 3 - N4 foci/20 × ﬁeld.
Stages of NASH. 0 - none, 1 - extensive zone 3 perisinusoidal ﬁbrosis,
2 - zone 3 perisinusoidal andportal or periportalﬁbrosis, 3 - bridging
ﬁbrosis and 4 - cirrhosis.
2.5. Hepatic lipid peroxidation
Malondialdehyde (MDA) is one of major aldehydic metabolites of
lipid peroxidation and has been used to reﬂect lipid peroxidation [21].
Lipid Peroxidation MDA Assay Kit (Beyotime, China) was used to mea-
sure MDA in the liver.) Normal - controls fedwith a regular diet, (ii) MCD -mice fedwith theMCD diet only and
f 1 × 106MSCs administered at 6 and 7 weeks of the 10-week experiment. At 10weeks, all
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Single-cell suspensions derived from splenic tissues (splenocytes)
were prepared by mechanical disruption, ﬁltered through a 40-μm cell
strainer (BD, USA), followed by lysis of red blood cells. For intracellular
cytokine staining, splenocytes were resuspended in complete RPMI
1640 medium (Gibco, Auckland, NZ) supplemented with 1 mmol/l
MEM sodium pyruvate, 0.1 mmol/l MEM nonessential amino acids,
2 mM L-glutamine, 100 IU penicillin, 100 mg/ml streptomycin and
4.5 × 10−5 M 2-mercaptoethanol. The cells were stimulated with
50 ng/ml phorbol 12-myristate 13-acetate (PMA), 1 μg/ml ionomycin
(Enzo life sciences, Farmingdale, USA) and 3 μg/ml brefeldin A
(eBioscience, CA, USA) for 5 h. Next, cells were stained for surface
markers using rat anti-mouse CD4-APC (eBioscience, CA, USA). For in-
tracellular staining, the cells were ﬁxed and permeabilized with
Cytoﬁx/Cytoperm buffers (BD Biosciences, USA) for 20 min at 4 °C and
then washed with permeabilization wash buffer (BD Biosciences,
USA). The Fc receptors were blocked with 2% rat serum and 10% bovine
serum albumin prior to intracellular cytokine staining followed by
staining with rat anti-mouse IFN-γ-FITC, IL-17A-PE or IL-6-FITC
(eBioscience, CA, USA). The cells were then analyzed using a
FACSCalibur and the data generated were analyzed using FlowJo 7.6.1
software (Tree Star, Inc., USA).Fig. 2.Morphology and immunophenotypic features of MSCs isolated frommouse compact bon
of compact bone chips. (B) Immunophenotypic features of MSCs. As shown in the upper panel
while negative surface markers of MSCs, such as CD11b, CD45 and CD135 were not expressed2.7. Statistical analysis
Data were expressed as means ± SDs (standard deviations). Graph
Pad PRISM (version 5.0) software were used for statistical analyses.3. Results
3.1. Cells isolated from compact bone are characterized as MSCs
As described above, MSCs were obtained from 2 to 3-week-old fe-
male C57BL/6 mice euthanized by cervical dislocation. Hematopoietic
cells were depleted and released cells discarded by ﬂushing with PBS
or α-MEM [20]. After 1–2 weeks in culture, cells were observed to
grow out from proximity of compact bone chips and appeared to be ﬁ-
broblast-like (MSCs), but not polygon shaped (osteocytes) (Fig. 2A). To
further identify adherent cells, immunophenotypic features were ana-
lyzed. As shown in the upper panel of Fig. 2B, the cells expressed surface
markers characteristic of MSCs, such as CD29 and CD44; while negative
surface markers of MSCs, such as CD11b, CD45 and CD135 were not
expressed (Fig. 2B, lower panel). Taken together, these ﬁndings indicate
that these cells were MSCs.e. (A) Photograph ofMSCsmorphology. Fibroblast-likeMSCs grew out from the proximity
of B, the cells expressed surface markers characteristic of MSCs, such as CD29 and CD44;
(B, lower panel). Representative images are shown for all panels.
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MSCs treatment
MCD diet-induced NASH has been reported to be accompanied by
weight loss [1]. Here, as compared with Normals, we also observed
weight loss in MCDmice when recorded at weeks 6 and 7 of the exper-
iment, prior to treatment with MSCs. Following MSC treatment, the
MCD+MSCmice began to showweight gains (Fig. 3A). As the aldehy-
dic metabolites of lipid peroxidation, MDA is often used to reﬂect lipid
peroxidation [21]. It was demonstrated that MCD diet induced-hepatic
MDA accumulation was hampered with MSCs treatment (Fig. 3B).
3.3. MCD diet-induced steatosis, ballooning and lobular inﬂammation were
attenuated by MSCs treatment
Hepatocytes containing fat vacuoles can be easily visualized as clear
bubbles following HE staining [2]. When compared with Normals, MCD
diet induced lipid deposition and inﬂammation within the liver, effects
that were reduced by MSCs treatment (Fig. 4A). As indicated by scores
obtained from the scales described above, increases in steatosis (Fig.
4B), ballooning (Fig. 4C) and lobular inﬂammation (Fig. 4D) as induced
by MCD were all decreased in response to MSC treatment.
3.4. MSCs treatment ameliorated MCD diet-induced liver ﬁbrosis
Progression of NASH is often accompanied with ﬁbrosis [2]. There-
fore, we also assessed the stages of ﬁbrosis in these cells as achieved
with picrosirius red staining. MCD fed mice showed a progression into
extensive ﬁbrogenesis within their livers whereas MSCs treatment re-
duced hepatic ﬁbrogenesis as observed in MCD + MSC mice (Fig. 5A).
Differences in ﬁbrosis stage scores and ﬁbrosis area between MCD and
MCD+MSCs mice were signiﬁcantly different (Fig. 5B, C).
3.5. MSCs treatment reduced percent of CD4+ IFN-γ+ and CD4+IL-6+ T
spleen cells
MSCs can interact with both innate and adaptive immune system
cells, leading to the modulation of several different effector functions
[9]. Analysis of spleen leukocytes was performed to explore the effect
of MSCs on immunological responses. We found that as compared
with Normals, percent of CD4+ IFN-γ+ and CD4+IL-6+ lymphocytes
that were associated with pro-inﬂammation were decreased with
MSCs (Fig. 6 A, B). However, percent of CD4+IL-17+ lymphocytes thatFig. 3.MCD diet-induced weight loss and hepatic lipid oxidation stress was hampered by MS
repeated measures ANOVA. (B) MSCs treatment with an intravenously injection of 1 × 106 M
examined by repeated measures ANOVA. (C) Hepatic lipid oxidation stress was determined byassociated with anti-inﬂammation show little change in MCD as well
as in MCD+MSCs splenocytes (Fig. 6 C).
4. Discussion
MSCs, also known as multipotent mesenchymal stromal cells, were
originally isolated by Friedenstein and his colleagues frombonemarrow
in 1976 [22], and have subsequently been found to exist in other organs
and tissues [20]. However, the method established by Friedenstein as
based on plastic adherence, has proved unsuccessful for mouse MSCs
(mMSCs) due to the low frequency of MSCs and the contamination of
hematopoietic cells in the culture [23]. A recent adaption of this proto-
col, which has offered an easy and reproducible method to harvest
mouse MSCs, has been provided by Heng Zhu [20]. In the present
study, we utilized this method and successfully isolated MSCs that
were ﬁbroblast-like and expressed putative surface markers of MSCs
such as CD29 and CD44, but not CD11b, CD45 and CD135, which was
consistent with a previous report [20].
Increasing evidence has been accruedwhich indicate thatMSCshave
a potential clinical value in the treatment of certain diseases [9]. Inter-
estingly, there is limited data available that show any promising or de-
sirable therapeutic effects of MSCs in ameliorating fulminant hepatic
failure, chronic liver ﬁbrosis and cirrhosis. Findings from a previous re-
port have demonstrated that fulminant hepatic failure can be induced
in Sprague-Dawley rats with an intraperitoneally administration of
two injections of 1.2 g/kg hepatotoxin, D-galactosamine. When these
rats were treated 24 h later with an intravenous injection of MSCs ly-
sates, cellular lysates showed an increased survival trend [12]. In the
carbon tetrachloride-induced hepatic ﬁbrosis model, Flk1 mouse MSCs
were systemically infused immediately or at 1 week after mice were
challengedwith carbon tetrachloride. In thesemice,mMSCs administra-
tion immediately and signiﬁcantly reduced carbon tetrachloride-in-
duced liver damage and collagen deposition [14]. In a previous study,
we indicated that compact bone-derived mMSCs ameliorated gross
and microscopic liver histopathology and reduced death of mice in
thioacetamide-induced FHF and also suppressed carbon tetrachloride-
induced chronic liver ﬁbrosis [19]. In addition, we also demonstrated
that MSC-CM tendentiously improves chronic liver ﬁbrosis [19].
Recently, it was reported by Boeykens that MSC-therapy could have
a limited effects on NASH, which was observed that MCD diet model
both serum CHE and TG levels of non-treated and cell-treated rats
with PHx after MCD remained signiﬁcantly lower as compared to
those of control rats [24]. Despite this, Boeykens also found that en-
hanced the recovery to normal body weight, liver weight and NASCs treatment. (A) Effects of MCD diet on body weight growth. P value was examined by
SCs administered at 6 and 7 weeks reversed MCD diet-induced weight loss. P value was
Lipid Peroxidation MDA Assay Kit. *P b 0.05 with t-TEST.
Fig. 4.MCD diet-induced steatosis, ballooning, and lobular inﬂammation were ameliorated by MSCs treatment. (A) HE staining of mice liver sections. Fat vacuoles (black arrows) and
inﬂammation foci (green arrows) were reduced by MSCs treatment in MCD + MSCs mice. Scale scores of steatosis (B), ballooning (C) and lobular inﬂammation (D) were all
signiﬁcantly decreased in MCD+MSCs versus MCD mice. Representative images are shown for all panels. The data are presented as the means ± SDs. *P b 0.05; **P b 0.01 with t-TEST.
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signiﬁcantly reduced MCD diet-induced weight loss, steatosis, balloon-
ing and lobular inﬂammation, which consistent with the report de-
scribed above. Altogether, it could be yet proposed that MSCs may
possess a potential clinical value upon NASH.
A primary basis for disease protection afforded by MSCs likely in-
volves their potent anti-inﬂammatory and immunomodulatory activi-
ties [25]. Mice injected with MSCs (5 × 106 MSCs/kg body weight)
showed that host T-cell responses to donor alloantigenswere decreased
in the majority of recipients [26]. There are data which indicate that
MSCs did not preferentially target any T-cell subset, and their capacity
for inhibition extended to B cells, with the result being that MSC-medi-
ated inhibition induces an unresponsive T-cell proﬁle. Such ﬁndings are
consistent with that observed in division arrest energy [27]. In our pre-
vious study, we also demonstrated the immunosuppressive effects of
MSC treatment, converting the body into an anti-inﬂammatory state
by up-regulating anti-inﬂammatory Treg cells and reducing pro-inﬂam-
matory Th1 and Th7 cells in thioacetamide-induced FHF and carbon tet-
rachloride -induced chronic liver ﬁbrosis [19]. In the present study,
among potential spleen leukocytes, we selected CD4+T cells to explore
the immunomodulatory effects of MSCs on NASH. We found that MSCs
treatment suppressed multiplication of CD4+ IFN-γ+ and CD4+IL-6+ TFig. 5. Improvement of MCD diet-induced liver ﬁbrogenesis byMSCs. (A) Picrosirius red stainin
Representative images are shown for all panels. The data are presented as the means ± SDs. *Pspleen cells, which was consistent with previous reports [25]. The mo-
lecular mechanism may be due to the molecules secreted by MSCs
[19]. Accordingly, we conclude that MSCs-mediated immunosuppres-
sion accounts for the ameliorative effects upon NASH.
In summary,MSCs isolated from compact bone have potential clinical
value uponNASH(summarized in Fig. 7).MSCs transplantation enhances
the resistance toMCDdiet-inducedNASH, as indicated by several param-
eters including reductions in MCD diet-induced weight loss, steatosis,
ballooning and lobular inﬂammation. As based upon these ﬁndings, the
ameliorative effects upon NASH by MSCs likely results from suppression
of activation of CD4+ IFN-γ+andCD4+IL-6+ lymphocytes. However, the
effectiveness andmechanics of treatment in regards to gender and age of
animals are unclear and remain to explore in the future.Author contributions
H.W. and D.W. conceived and designed the experiments. D.W., J.J.,
H.C., C.L. and Y. L. performed the experiments. D.N., C.L., Y. W. and L.Y.
collected and analyses data. H.W., and L.Y. wrote the manuscript. H.W.
and C.L. contributed to the guidance of experiments and contributed
to the ﬁnal manuscript. All authors reviewed the manuscript.g of mice liver sections. (B) Scale scores of liver ﬁbrosis. (C) Quantiﬁcation of ﬁbrosis area.
b 0.05 with t-TEST.
Fig. 6. Effects of MSCs on CD4+ T cells differentiation. For intracellular cytokine staining, splenocytes were treated with 50 ng/ml PMA, 1 μg/ml ionomycin and 3 μg/ml brefeldin A for 5 h.
The cells were stained for surfacemarkers using rat anti-mouse CD4. For intracellular staining, the cells wereﬁxed and permeabilizedwith Cytoﬁx/Cytoperm buffers for 20min at 4 °C and
then washed with permeabilization wash buffer. The Fc receptors were blocked with 2% rat serum and 10% bovine serum albumin prior to intracellular cytokine staining. Next, the cells
were stained with rat anti-mouse IFN-γ, IL-6 and IL-17A. (A) CD4+ IFN-γ+, (B) CD4+ IL-6+ and (C) CD4+IL-17A+ lymphocytes was analyzed by ﬂow cytometry. Representative data are
shown for all panels.
Fig. 7. Compact bone-derivedMSCs have potential clinical value uponNASH.MSCs transplantation enhances the resistance toMCDdiet-induced NASH, as indicated by several parameters
including reductions in MCD diet-induced weight loss, steatosis, ballooning and lobular inﬂammation. As based upon these ﬁndings, the ameliorative effects upon NASH by MSCs likely
results from suppression of activation of CD4+ IFN-γ+ and CD4+IL-6+ lymphocytes.
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